GlassScriptPhysician profile
Andrea Katz
NPI 1295927739
$2,132.91
in general payments reported to CMS, 2019-2025
37 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $220 · 2021: $188 · 2022: $212 · 2023: $662 · 2024: $240 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.97 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $257.37 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $173.33 | 2019-2025 | Eliquis, Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $132.51 | 2021-2023 | Imbruvica |
| Advanced Accelerator Applications | $124.48 | 2019-2020 | |
| Abbvie INC. | $124.32 | 2019-2023 | |
| Celgene Corporation | $116.23 | 2019-2025 | Reblozyl |
| Incyte Corporation | $88.35 | 2021-2022 | |
| Gilead Sciences, INC. | $85.60 | 2023-2025 | Trodelvy |
| Seagen INC. | $78.97 | 2020-2023 | Tivdak, Adcetris, Tukysa |
| Astrazeneca Pharmaceuticals LP | $63.99 | 2022-2023 | Enhertu |
| Genentech USA, INC. | $62.15 | 2019-2025 | Venclexta |
| Fennec Pharmaceuticals, INC. | $60.37 | 2024 | Pedmark |
| Eisai INC. | $59.26 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $54.97 | 2020 | |
| Glaxosmithkline, LLC. | $53.02 | 2022-2023 | Zejula |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $47.90 | 2023-2024 | Zoladex |
| Genzyme Corporation | $45.72 | 2022-2025 | |
| Kite Pharma, INC. | $42.89 | 2021-2023 | |
| Daiichi Sankyo INC. | $40.00 | 2023-2025 | Enhertu, Vanflyta |
| Pharmacosmos Therapeutics INC. | $39.65 | 2022-2024 | Cosela |
| Cti Biopharma Corp. | $38.56 | 2022-2023 | Vonjo |
| Astellas Pharma US INC | $34.59 | 2019-2024 | Xtandi |
| Pfizer INC. | $26.54 | 2019-2025 | |
| Stemline Therapeutics INC. | $25.30 | 2023 | Orserdu |
| Servier Pharmaceuticals LLC | $24.01 | 2023 | |
| Karyopharm Therapeutics INC. | $23.73 | 2025 | Xpovio |
| Sanofi-Aventis U.S. LLC | $23.70 | 2019 | |
| Merck Sharp & Dohme LLC | $22.43 | 2025 | Keytruda |
| Lilly USA, LLC | $22.20 | 2023 | Jaypirca, Retevmo, Verzenio |
| Acrotech Biopharma INC. | $21.84 | 2023 | Beleodaq |
| Emd Serono, INC. | $21.08 | 2023 | Bavencio |
| Janssen Pharmaceuticals, INC | $19.13 | 2023 | Xarelto |
| Mirati Therapeutics, INC. | $19.00 | 2023 | Krazati |
| Beigene USA, INC. | $18.86 | 2024 | Brukinsa |
| Aurobindo Pharma USA, INC. | $13.87 | 2019 | |
| Secura Bio, INC. | $13.68 | 2023 | Copiktra |
| Rigel Pharmaceuticals, INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.